AlvaroUArandaMD

PubMed

• 71 citations
  Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis
  Camille M. Moore, Rachel Z. Blumhagen, Ivana V. Yang, Avram D Walts, Julie Powers
  American Journal of Respiratory and Critical Care Medicine. 2019-07-15
• 22 citations
  Idiopathic Pulmonary Fibrosis Is Associated with Common Genetic Variants and Limited Rare Variants.
  Anna L Peljto, Rachel Z Blumhagen, Avram D Walts, Jonathan Cardwell, Julia Powers
  American Journal of Respiratory and Critical Care Medicine. 2023-05-01
• 8 citations
  Riociguat improves health-related quality of life for patients with pulmonary arterial hypertension: results from the phase 4 MOTION study:
  Namita Sood, Alvaro Aranda, David Platt, Anneliese LaRose, Frank Kleinjung
  Pulmonary Circulation. 2019-02-19

Journal Articles

• Latin American Asthma Insight Management Project  
  Aranda A, 1/1/2013
• Consensus report on the use of Clindamycin in the treatment of PCP in patients with AIDS  
  Aranda A et al, The Lancet, 1/1/1991
• Clindamycin for toxoplasma encephalitis in AIDS  
  Aranda A et al, The Lancet, 1/1/1991

Abstracts/Posters

• PR Pulmonary Hypertension Registry
  Aranda A, Chest, Chest International Congress, Madrid, Spain, 1/1/2014
• Noncompliance after acceptance of nasal continuous positive airway for sleep apnea.
  Jose E. Perez, M.D., W. McDowell Anderson, MD, FCCP, Alvaro U. Aranda, MD, John T. Sharp, MD, FCCP, ACCP USA, 1/27/1993
• Identification of mechanism of respiratory muscle fatigue
  Aranda A et al, ARRD, ATS/ALA Convention, Miami, FL, 1/1/1992
• Clinical efficay of Aerolized Clindamcycin and oral primaquine in P. Carinii in AIDS patients.
  Aranda A et al, 6th International Symposium on Infection in Immune-compromised Host, Peebles, Scotland, 1/1/1990
• Join now to see all

Lectures

• Prevnar & Vaccines 
  Multiple Locations, 2015, 2016, 2017 - 1/1/2017
• Asthma 
  Multiple Locations, 1997, 1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 20 - 1/1/2017
• COPD 
  Multiple Locations, 1996, 1997, 1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 20 - 1/1/2017
• Infectious Disease 
  Multiple Locations, 1997, 1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 20 - 1/1/2017
• Sleep-Insomnia 
  Multiple Locations, 2014, 2015, 2016, 2017 - 1/1/2017
• Baseline Demographics of the Prospective, Multicenter, Single-Arm, Open-Label, Phase IV MOTION Study of Riociguat in Pulmonary Arterial Hypertension 
  1/1/2016
• Rhinitis 
  Multiple Locations, 1997, 1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 20 - 1/1/2013
• Coagulation 
  Multiple Locations, 1997, 1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 20 - 1/1/2011
• Broncial Asthma 
  Multiple Locations, 1997, 1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 20 - 1/1/2011
• Pulmonary Embolism 
  Multiple Locations, 1997, 1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 20 - 1/1/2011
• Influenza 
  Multiple Locations, 1996, 1997, 1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 20 - 1/1/2010
• Rhinitis and Allergy 
  Multiple Locations, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009 - 1/1/2009
• Pneumonia 
  Multiple Locations, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009 - 1/1/2009
• Narcolepsy and Sleep Disorders 
  Multiple Locations, 2004, 2005, 2006 - 1/1/2006
• Sepsis 
  Multiple Locations, 2000, 2001, 2002, 2003, 2004, 2005, 2006 - 1/1/2006
• Critical Care and Sedation 
  Multiple Locations, 1999, 2000, 2001, 2002 - 1/1/2002
• Noncompliance after acceptance of nasal continuous positive airway for sleep apnea. 
  1/1/1993
• Join now to see all